SCHEMBL10011182

SCHEMBL10011182

Cc1cc(-n2nc(Nc3cccc(OC(F)(F)F)c3)cc2COCc2ccccc2)ccn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 4/20 0.41
▸ IGF1R P08069 2/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ KCNH2 Q12809 1/20 0.41
▸ GPR142 Q7Z601 1/20 0.41
▸ GALR2 O43603 1/20 0.40
▸ GALR1 P47211 1/20 0.40
▸ SLC5A1 P13866 2/20 0.39
▸ RXRA P19793 2/20 0.38
▸ GRIN1 Q05586 2/20 0.38
▸ GRIN2B Q13224 2/20 0.38
▸ CTSC P53634 1/20 0.37
▸ NPY5R Q15761 1/20 0.37
▸ DYRK1A Q13627 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ GSK3B P49841 1/20 0.36
▸ PDK1 Q15118 1/20 0.36
▸ PDK2 Q15119 1/20 0.36
▸ PDK3 Q15120 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10008198 0.91 GALR2 (0.43) IGF1RGALR2GALR1SLC5A1RXRA
SCHEMBL10008700 0.88 SLC2A1 (0.46) MAPK1CYP2D6CYP2C9KCNH2GPR142
SCHEMBL1506242 0.85 MAPK1 (0.46) MAPK1IGF1RCYP2D6CYP2C9KCNH2
SCHEMBL1506248 0.83 MAPK1 (0.44) MAPK1IGF1RCYP2D6CYP2C9KCNH2
SCHEMBL10010076 0.83 KDR (0.44) MAPK1CDK2GSK3B
SCHEMBL10008965 0.83 MAPK1 (0.42) MAPK1GSK3B
SCHEMBL10009879 0.82 MAPK1 (0.45) MAPK1IGF1RCYP2D6CYP2C9KCNH2
SCHEMBL27981727 0.82 MAPK1 (0.45) MAPK1IGF1RCYP2D6CYP2C9KCNH2
SCHEMBL1506469 0.81 MAPK1 (0.46) MAPK1IGF1RCYP2D6CYP2C9KCNH2
SCHEMBL10010866 0.81 MAPK1 (0.46) MAPK1IGF1RCYP2D6CYP2C9KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8791144-B2 Substituted N-phenyl-1-(4-Pyridinyl)-1H-pyrazol-3-amines JANSSEN PHARMACEUTICA NV (BE) 2014-07-29 — — US disclosed
EP-2491024-B1 SUBSTITUTED N-PHENYL-1-(4-PYRIDINYL)-1H-PYRAZOL-3-AMINES JANSSEN PHARMACEUTICA NV (BE) 2013-11-20 — — EP disclosed
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines JANSSEN PHARMACEUTICA NV (BE) 2012-07-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120172354-A1 Substituted N-Phenyl-1-(4-Pyridinyl)-1H-Pyrazol-3-Amines CHRM1, CHRNA1, CHRM3 MAPK1 1404/4885IGF1R 602/4885CYP2D6 1495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback